Tango Therapeutics Reports 82% ORR in 2L/3L PDAC Patients
Tango Therapeutics reported an 88% 9-month PFS rate among 22 efficacy-evaluable patients treated with vopimetostat plus daraxonrasib; median PFS was not yet reached. The company expects a registrational front-line Phase 3 trial in MTAP-deleted PDAC to start in 1H 2027.